Lanthaan Viatris (Lanthanum)

Lanthaan Viatris is used to manage phosphate metabolism disorders, primarily hyperphosphatemia associated with chronic kidney disease.

• Hyperphosphatemia in dialysis patients: lowers serum phosphate levels to target range.
• Hyperphosphatemia in non‑dialysis CKD: helps maintain phosphate within recommended limits.
• CKD with secondary hyperparathyroidism: reduces phosphate burden contributing to disease management.

• Lanthanum acts as a non‑absorbed cation that binds dietary phosphate ions in the gastrointestinal lumen, forming insoluble lanthanum‑phosphate complexes. These complexes are not absorbed and are eliminated in the feces, thereby decreasing the amount of phosphate available for intestinal absorption and reducing serum phosphate concentrations.

Lanthaan Viatris may cause adverse reactions, most of which involve the gastrointestinal system.

Common Side Effects

• Nausea: mild to moderate discomfort in the stomach.
• Constipation: reduced bowel movements.
• Abdominal pain: cramping or discomfort.
• Flatulence: increased gas.

Serious or Rare Side Effects

• Gastric bezoar formation: accumulation of lanthanum complexes causing obstruction.
• Severe gastrointestinal obstruction: blockage requiring medical intervention.
• Anaphylactic reaction: rare severe allergic response.

When prescribing Lanthaan Viatris, several precautions should be observed to ensure patient safety.

• Monitor serum phosphate: adjust therapy based on regular laboratory measurements.
• Assess calcium balance: watch for hypercalcemia when used with calcium supplements.
• Use cautiously in bowel obstruction: avoid in patients with known gastrointestinal blockage.
• Avoid in patients with known hypersensitivity to lanthanum or excipients.
• Pregnancy and lactation: limited data, prescribe only if potential benefit outweighs risk.
• Store at room temperature: keep in original container, protect from moisture and heat.

Lanthaan Viatris can interact with other medicines, affecting its phosphate‑binding capacity or patient safety.

Major Interactions (Avoid)

• Aluminum‑containing antacids: may bind phosphate and reduce effectiveness.
• Iron supplements: can interfere with lanthanum binding.
• Calcium carbonate: may compete for binding sites, diminishing phosphate reduction.

Moderate Interactions (Monitor Closely)

• Vitamin D analogues: monitor calcium and phosphate levels.
• ACE inhibitors: observe renal function and electrolyte balance.
• Diuretics: watch for changes in electrolyte status.